Skip to content

CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved.

AstraZeneca full-year results: where next for the share price?

The British-Swedish pharmaceutical company will unveil its full-year results on Valentine’s Day, with investors hoping its earnings update will beat estimates for a fifth consecutive quarter and push its share price higher.

FTSE 100 Source: Bloomberg

AstraZeneca will unveil its full-year results on Valentine’s Day (14 February), with investors hoping the drug maker will beat estimates for a fifth consecutive quarter and drive its share price higher.

Over the last 12 months, the drug maker’s back-to-back earnings streak has helped its share price soar, with the stock up 33% – outperforming the broader market, with the FTSE 100 up just 5% over the same period.

AstraZeneca’s share price has also outperformed rivals like GlaxoSmithKline and Pfizer, with the former up 9% over the last 12 months to £16.98 as of 14:32 (GMT) on Wednesday, while the latter is down close to 9% to $38.06.

AstraZeneca is trading at £76.70 a share.

Looking to trade AstraZeneca? Find out how to buy, sell and short AstraZeneca shares now.

AstraZeneca: technical analysis

Shares in Astrazeneca have been on a relatively consistent rise over the years, with 2019 providing a welcome ramp-up in the rate of growth for the stock, according to senior market analyst at IG, Josh Mahony.

‘That uptrend is something we can utilise for our benefit, with a continuation expected until the price tells us otherwise,’ Mahony said.

‘The rebound seen last week came from a pullback into trendline and Fibonacci (61.8%) support, with that rally providing confidence that the rising channel remains relevant.’

While we are seeing some weakness today, this is likely to be a precursor to further gains,’ he added.

You can go long or short AstraZeneca with IG using derivatives like CFDs.

Chart1
Chart1

The four-hour chart highlights how the rebound seen last week provided a push through the £77.21 resistance level, negating the creation of lower highs that have been playing out since the January peak of £79.48.

This points towards a likely end to that period of weakness and a resumption of the wider bullish trend. With that in mind, any further short-term downside would be deemed a good buying opportunity so long as the price does not break below £73.98.

Investors should watch for whether AstraZeneca breaks below £76.10 to bring about that short-term period of weakness and retracement of the £73.98 - £78.03 rally. Should that pullback occur, this stock would look like good value around the 61.8-76.4% Fibonacci zone (£74.94 - £75.53).

Chart2
Chart2

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.

Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Tuesday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.